𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

✍ Scribed by Talpaz, Moshe; Shah, Neil P.; Kantarjian, Hagop; Donato, Nicholas; Nicoll, John; Paquette, Ron; Cortes, Jorge; O'Brien, Susan; Nicaise, Claude; Bleickardt, Eric; Blackwood-Chirchir, M. Anne; Iyer, Vishwanath; Chen, Tai-Tsang; Huang, Fei; Decillis, Arthur P.; Sawyers, Charles L.

Book ID
120754800
Publisher
Massachusetts Medical Society
Year
2006
Tongue
English
Weight
443 KB
Volume
354
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib treatment for Philadelphia chr
Dasatinib treatment for Philadelphia chromosome-positive leukemias : Practical considerations
✍ Hanna Jean Khoury; François Guilhot; Timothy P. Hughes; Dong-Wook Kim; Jorge E. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract Dasatinib is a highly potent Bcr‐Abl inhibitor that is approved for the treatment of imatinib‐resistant or ‐intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome‐positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with

Imatinib mesylate in Philadelphia chromo
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood
✍ E. Anders Kolb; Qiulu Pan; Marc Ladanyi; Peter G. Steinherz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract ## BACKGROUND Initial treatment for adult patients with Philadelphia chromosome‐positive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib mesylate. However, to our knowledge, there are few data regarding imatinib safety, efficacy, and response monitoring in patients age